Powering the Next Wave of Precision Genetic Medicines — Together
Our goal is to maximize the potential of our SORT LNP delivery technology even beyond those rare diseases in our pipeline so that more patients may realize the full benefit of genetic medicines.
We believe in winning together and importantly, winning in our shared mission to help more patients in need. Together, we can power the next wave of precision genetic medicines.
“We can enhance the potency of any genetic cargo by packaging it using our SORT LNP platform and delivering it directly to the organs and cells impacted by disease. This creates vast opportunities to address a wide range of unmet medical needs not possible with current technologies.”
Shehnaaz Suliman, M.D., M.B.A., M.Phil.
Chief Executive Officer

Strategic Investment from the Cystic Fibrosis Foundation
ReCode receives strategic investment from the Cystic Fibrosis Foundation of up to $15 million to support preclinical studies needed for an Investigational New Drug (IND) application and early clinical development of ReCode’s CFTR mRNA therapy for cystic fibrosis.

Strategic Collaboration Explores Single Vector Gene-Editing Platform
ReCode signs multi-year research collaboration and option agreement with AskBio which will combine ReCode’s SORT LNP technology with AskBio’s gene editing and DNA cargoes to potentially discover precision genetic medicines for the liver and lung.
Events & Presentations
March 6, 2023
|
Boston, MA
Cowen 43rd Annual Healthcare Conference
Our CSO, David Lockhart, and SVP of Business Development, Angèle Maki, are attending.
March 16, 2023
|
Basel, Switzerland
RNA Leaders Congress
David Lockhart, Ph.D., President & Chief Scientific Officer, presenting: “Delivering the Future of Genetic Medicines, Unconstrained by Delivery”
March 20, 2023
|
Basel, Switzerland
BIO Europe Spring
Angèle Maki, Ph.D., SVP of Business Development, presenting: Company Presentation
March 21, 2023
|
Whistler, B.C.
Keystone Genome Precision Engineering
Dan Siegwart, ReCode Co-Founder, presenting: “Selective Organ Targeting (SORT): A Strategy for Effective Tissue Specific mRNA Delivery and CRISPR/Cas Gene Editing”
March 28, 2023
|
Virtual
BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines
David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a panel discussion titled “Novel LNPs Targeting Diverse Tissues” at 10:00 a.m. ET
March 29, 2023
|
Dubrovnik, Croatia
ECFS Basic Science Conference
Daniella Ishimaru, PhD, Principal Scientist, presenting: “CFTR functional rescue after delivery of nebulized LNP/mRNA to primary human bronchial epithelial cells derived from patients with different CFTR genotypes”
Do you want to be on the frontier of a new generation of precision genetic medicines?
Contact us at [email protected]